Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARLYS: Edaravone Dexborneol in Acute Ischemic Stroke
NCT05885919Phase 3Unknown
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Edaravone Dexborneol with Placebo (2 arms). Primary endpoint: Proportion of modified Rankin Scale 0-2 at 90 days. Status: unknown.
02
Drugs
edaravonedexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05885919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05885919.